Peter Zill
Biographic Data
| ID | 7374429 |
|---|---|
| NAME | Peter Zill |
| GIVEN NAMES | Peter |
| FAMILY NAME | Zill |
| SIGNATURE | ZILL P |
| AFFILIATIONS | Ludwig-Maximilians-Universität München |
| ORCID | 0000-0003-1068-5886 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2023 |
| H-INDEX | 0 |
The multimodal Munich Clinical Deep Phenotyping study to bridge the translational gap in severe mental illness treatment research
The identification of cross-diagnostic and diagnosis-specific biotype-informed subgroups of patients and the translational dissection of those subgroups may help to pave the way toward precision medicine with artificial intelligence-supported tailored interventions and treatment. This aim is particularly important in psychiatry, a field where innovation is urgently needed because specific symptom domains, such as negative symptoms and cognitive d…
Biobanking in everyday clinical practice in psychiatry—The Munich Mental Health Biobank
Translational research on complex, multifactorial mental health disorders, such as bipolar disorder, major depressive disorder, schizophrenia, and substance use disorders requires databases with large-scale, harmonized, and integrated real-world and research data. The Munich Mental Health Biobank (MMHB) is a mental health-specific biobank that was established in 2019 to collect, store, connect, and supply such high-quality phenotypic data and bio…
Efficacy of Sertraline Plus Placebo or Add-On Celecoxib in Major Depressive Disorder
Introduction: Previous research delivers strong indications that inflammatory activation leads to treatment resistance in a subgroup of patients with Major Depressive Disorder (MDD). Thus, tailored interventions are needed. The present study aimed to find potential biomarkers that may enable patients to be stratified according to immune activation. Methods: A phase IIa randomized placebo-controlled trial was performed to assess levels of inflamma…
No prominent works on this page.
Efficacy of Sertraline Plus Placebo or Add-On Celecoxib in Major Depressive Disorder
Introduction: Previous research delivers strong indications that inflammatory activation leads to treatment resistance in a subgroup of patients with Major Depressive Disorder (MDD). Thus, tailored interventions are needed. The present study aimed to find potential biomarkers that may enable patients to be stratified according to immune activation. Methods: A phase IIa randomized placebo-controlled trial was performed to assess levels of inflamma…
Biobanking in everyday clinical practice in psychiatry—The Munich Mental Health Biobank
Translational research on complex, multifactorial mental health disorders, such as bipolar disorder, major depressive disorder, schizophrenia, and substance use disorders requires databases with large-scale, harmonized, and integrated real-world and research data. The Munich Mental Health Biobank (MMHB) is a mental health-specific biobank that was established in 2019 to collect, store, connect, and supply such high-quality phenotypic data and bio…
The multimodal Munich Clinical Deep Phenotyping study to bridge the translational gap in severe mental illness treatment research
The identification of cross-diagnostic and diagnosis-specific biotype-informed subgroups of patients and the translational dissection of those subgroups may help to pave the way toward precision medicine with artificial intelligence-supported tailored interventions and treatment. This aim is particularly important in psychiatry, a field where innovation is urgently needed because specific symptom domains, such as negative symptoms and cognitive d…
Medicine (3 works) · Psychiatry (3 works) · Tryptophan and brain disorders (3 works) · Biobank (2 works) · Bioinformatics (2 works) · Clinical trial (2 works) · Major depressive disorder (2 works) · Mood (2 works) · Pathology (2 works) · Psychology (2 works)